Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Editas adds CFO and $120m in Series B round

Editas Medicine, a leading genome editing company, today announced that it has raised $120 million in a highly oversubscribed Series B private financing. The financing assembles a broad syndicate of leading public and private investors who underpin many of the most innovative biopharmaceutical and technology companies.

Read the full article…

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , , , , , , , | Leave a comment

Jeremy Levin hauls in $75m Series B for Ovid

Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, announced today that it has completed a Series B financing totaling $75 million. Fidelity Management and Research Company led the investment syndicate, which included Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates (on behalf of certain clients), Redmile Group, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors. Existing Ovid investors, including DoubleLine Equity Healthcare Fund, LLC, also participated in the financing.

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , | Leave a comment

KalVista Pharmaceuticals adds $33m and Directors in Series B round

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). Alongside the existing investors, Novo A/S and SV Life Sciences, the round included additional international healthcare investors experienced in plasma kallikrein targeted mechanisms led by RA Capital Management and including Longwood Fund and Venrock.

Read the full article…

Posted in M&A Finance and Funding | Tagged , , , , , , | Leave a comment

Epigenetics interest garners Syndax Pharmaceuticals $26.6m Series B

Authored by Karl Simpson

Read the full article…

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Massachusetts biotech continues to excite with new investments

Authored by Karl Simpson

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Ultragenyx focused on ultra-rare disease future

Authored by Paul Foster

Read the full article…

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap